BK-5-MAPB

βk-5-MAPB, or BK-5-MAPB, is an entactogen of the benzofuran and cathinone groups which is related to both 5-MAPB and methylone. It was patented by Matthew Baggott and Tactogen and is under investigation by Tactogen for potential medical use.^[1][2][3][4]

BK-5-MAPB

Clinical data
Other names	BK-5-MAPB
Drug class	Serotonin–norepinephrine–dopamine releasing agent; Entactogen; Stimulant
Identifiers
IUPAC name 1-(1-benzofuran-5-yl)-2-(methylamino)propan-1-one
CAS Number	2855950-94-4 Y
PubChem CID	163585306
ChemSpider	129866921
ChEMBL	ChEMBL5397369
Chemical and physical data
Formula	C12H13NO2
Molar mass	203.241 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C(=O)C1=CC2=C(C=C1)OC=C2)NC
InChI InChI=1S/C12H13NO2/c1-8(13-2)12(14)10-3-4-11-9(7-10)5-6-15-11/h3-8,13H,1-2H3 Key:GKZGRACLZFHCFE-UHFFFAOYSA-N

Pharmacology

It acts as a monoamine releaser with selectivity for serotonin and has a similar potency to MDMA.^{[1][2][5][3][6]} In terms of monoamine release, (S)-βk-5-MAPB has shown a DATTooltip dopamine transporter/SERTTooltip serotonin transporter ratio of 0.6 and a DAT/NETTooltip norepinephrine transporter ratio of 2.7, while (R)-βk-5-MAPB has shown a DAT/SERT ratio of 18 and a DAT/NET ratio of 1.9.^[3]

In rodent drug discrimination tests, (S)-βk-5-MAPB fully substitutes for MDMA whereas (R)-βk-5-MAPB partially substitutes for MDMA and dextroamphetamine at different doses, (R)-βk-5-MAPB and (S)-βk-5-MAPB both generalize to dextroamphetamine, and (S)-βk-5-MAPB but not (R)-βk-5-MAPB substitutes for DOM.^[4] Hence, (S)-βk-5-MAPB shows entactogen-, psychedelic-, and stimulant-like effects, whereas (R)-βk-5-MAPB shows more stimulant-like effects, some entactogen-like effects, and no psychedelic-like effects.^[4] In other tests, both (S)-βk-5-MAPB and (R)-βk-5-MAPB showed stimulant-like pro-impulsive effects, but (S)-βk-5-MAPB was more potent than (R)-βk-5-MAPB.^[7]

See also

• Substituted benzofuran
• Substituted cathinone
• βk-6-MAPB